Protocol Ledger

NCT07564726 · Phase III · COMPLETED

Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

Interventional Phase III clinical trial protocol NCT07564726 sponsored by Celltrion Pharm in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-05 Enrollment: 163 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07564726
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)163 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07564726
Protocol FieldVerified Registry Value
NCT IdentifierNCT07564726
Consolidated Lead SponsorCelltrion Pharm
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment163 participants (ACTUAL)
Registered Start Date2022-08-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07564726
Hospital Research SiteLocationSite Profile
Pusan National University HospitalBusan, South KoreaOpen Hospital Dossier ->
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI